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Head and neck cancer is the sixthmost common type of Cancer worldwide. Since conventional treatment regimens are nonselective
and are associated with systemic toxicities, intense investigations focus on molecular targeted therapy with high selectivity and low
adverse effects. mTOR signaling pathway has been found to be activated in head and neck cancer, making it attractive for targeted
therapy. In addition, expression levels of mTOR and downstream targets eIF4E, 4EBP1, S6K1, and S6 are potential diagnostic
and prognostic biomarkers for head and neck cancer. mTOR inhibitors, such as rapamycin and its derivatives temsirolimus and
everolimus, exhibit inhibitory effects on head and neck cancer in both in vitro cell line model and in vivo xenograft model. A large
number of clinical trials have been initiated to evaluate the therapeutic effects of mTOR inhibitors on patients with head and neck
cancer. mTOR inhibitor has potential as a single therapeutic agent or in combination with radiation, chemotherapeutic agents, or
other targeted therapeutic agents to obtain synergistic repression on head and neck cancer.
1. Introduction
Head and neck cancer is the sixth most common type of
cancer worldwide, with about 650,000 new cases in the world
every year [1]. Tobacco and alcohol consumption is a main
risk factor for head and neck cancer [1]. In addition, accu-
mulating evidence has shown that human papillomavirus
and Epstein-Barr virus are associated with carcinogenesis in
oropharyngeal cancers and nasopharyngeal cancers, respec-
tively [2, 3]. The treatment methods for head and neck can-
cer include surgery, radiotherapy, and chemotherapy [4].
Patients with early stages of disease are treated by surgery and
radiotherapy, while patients with advanced stages of disease
are administrated by surgery and chemoradiotherapy [4].
Platinum-based agents (cisplatin/carboplatin), taxane agents
(docetaxel/paclitaxel), and 5-fluorouracil are the most com-
mon chemotherapeutic agents for head and neck cancer [4–
7] (Table 1).
Despite advances in treatment methods for head and
neck cancer, the survival rate has not been largely improved
[4]. The major reason is that conventional treatment regi-
mens are nonselective and are related with systemic toxicities
[8, 9]. Therefore, intense investigations focus on alternative
treatment strategies with less systemic toxicities for head
and neck cancer. Since molecular targeted therapy has high
selectivity and low adverse effects, it exhibits promise as
an alternative treatment strategy for head and neck cancer.
Multiple molecular signaling pathways have been found to
be dysregulated in head and neck cancer, making it attractive
for targeted therapy.
Targeted therapy focuses on oncogenic signaling path-
ways involved in carcinogenesis of head and neck cancer,
such as epidermal growth factor receptor (EGFR), human
epidermal growth factor receptor 2 (HER-2), vascu-
lar endothelial growth factor receptor (VEGFR), insulin
growth factor-1 receptor (IGF-1R), MET receptor, tran-
scriptional factor nuclear factor-kappa B (NF-κB), and
phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian tar-
get of rapamycin (mTOR) pathway [10, 11]. Clinical and
preclinical investigations have developed some promising
targeted agents for head and neck cancer including EGFR
inhibitors (cetuximab, panitumumab, zalutumumab, nimo-
tuzumab), EGFR tyrosine kinase inhibitors (gefitinib,
erlotinib), dual EGFR/HER-2 kinase inhibitors (lapatinib,
afatinib), VEGFR inhibitor (bevacizumab), VEGFR tyrosine
kinase inhibitors (sorafenib and sunitinib), IGF-1R inhibitor
(figitumumab), MET tyrosine kinase inhibitors (crizotinib,
foretinib), mTOR inhibitors (rapamycin, everolimus, tem-
sirolimus, ridaforolimus, Torin1, PP242, and PP30), and
proteasome inhibitor (bortezomib) (Figure 1) [10, 11].
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Table 1: Chemotherapeutic model for head and neck cancer.
Chemotherapeutic agents Treatment regimens References
Platinum-based agents
(cisplatin/carboplatin)
Single agent or in
combination with
5-fluorouracil or taxane
agents
[5]
Taxane agents
(docetaxel/paclitaxel)
In combination with
cisplatin or
5-fluorouracil
[6]
5-Fluorouracil
In combination with
cisplatin or taxane
agents
[7]
mTOR signaling pathway has been found to be activated
and expression levels of mTOR and downstream proteins
are potential diagnostic and prognostic biomarkers for head
and neck cancer. Furthermore, mTOR inhibitors exhibit
inhibitory effects on head and neck cancer. Therefore, this
paper emphasizes on dysregulated mTOR signaling pathway
and the role of mTOR inhibitors in head and neck cancer.
2. mTOR Signaling Pathway in Head and
Neck Cancer
mTOR is an important downstream signal of PI3K/AKT/
mTOR signaling pathway and it is activated in head and neck
cancer [12]. The structure of mTOR contains N-terminal
tandem HEAT repeats, FAT domain, FATC domain, FRB
domain, and C-terminal kinase domain [12]. There are two
distinct mTOR complexes designated as mTOR complex 1
(mTORC1) and mTOR complex 2 (mTORC2) (Figure 2)
[13, 14]. mTORC1 is composed of mTOR, regulatory-associ-
ated protein of mTOR (Raptor) and mLST8 [15]. mTORC2
is comprised of mTOR, rapamycin-insensitive companion
of mTOR (Rictor), mLST8 and mammalian stress-activated
protein kinase interacting protein (mSIN1) [14]. mTORC1
is a nutrition- and rapamycin-sensitive complex, while
mTORC2 is insensitive to rapamycin [16, 17].
mTORC1 is regulated by multiple signals, such as growth
factors, nutrients, energy status, and oxygen and cellular
stress [13, 14]. mTORC1 promotes protein synthesis, pro-
liferation, cell survival, ribosome biogenesis, angiogenesis,
migration, invasion, and metastasis by phosphorylation of
ribosomal protein S6 kinase 1 (S6K1) and eukaryotic initia-
tion factor 4E (eIF4E)-binding protein 1 (4EBP1) (Figure 2)
[16, 18–20]. The phosphorylation of 4EBP1 results in the
release of eIF4E. Subsequently, the free eIF4E enhances
the translation of c-myc, cyclin D1, VEGF, and matrix
metalloproteinase-9 (MMP-9), thus promoting cell survival,
angiogenesis, invasion and metastasis [21–23]. The activa-
tion of S6K1 promotes ribosome biogenesis via upregula-
tion of ribosomal protein S6 [24]. mTORC2 functions in
actin remodeling, cell-cycle progression, and cell survival
through the regulation of protein kinase Cα (PKCα) and
glucocorticoid-induced protein kinase 1 (SGK1) [17, 25].
Some studies have demonstrated that expression levels of
mTOR and downstream targets eIF4E, 4EBP1, S6K1, and S6
are potential diagnostic and prognostic biomarkers for head
and neck cancer. In an experiment to evaluate mTOR protein
expression in 25 patients with laryngeal carcinoma treated
with postoperative radiotherapy, it was found that high
expression of mTOR was a prognostic marker for high risk
of recurrence after postoperative radiotherapy [26]. Elevated
level of eIF4E in tumor-free surgical margins was correlated
with local-regional recurrence in patients with head and
neck cancer [27–29]. Increased level of phosphorylated active
form of S6 was observed in cell lines and tumor tissues from
patients with head and neck cancer [29–31]. The mRNA
level of 4EBP1 was repressed, while the mRNA expression
of S6K1 was enhanced in tumors of patients with oral squa-
mous cell carcinoma [29]. Expressions of phosphorylated
S6K1 and phosphorylated 4EBP1 were regulated by LMP1
and were associated with overall survival of patients with
nasopharyngeal carcinoma (NPC), indicating that they were
potential prognostic biomarkers for NPC patients [32]. Clark
et al. carried out an experiment to find the best molecular
markers in the mTOR pathway for head and neck cancer
[33]. It was found that phosphorylated mTOR exhibited
better sensitivity and specificity than phosphorylated 4EBP1
in differentiating tumor from normal mucosa from patients
with head and neck cancer [33].
3. mTOR Inhibitors in Head and Neck Cancer
mTOR signaling pathway was activated in head and neck
cancer, making it attractive for targeted therapy. Two types of
mTOR inhibitors designated as first-generation and second-
generation inhibitors have been developed to interrupt
mTOR [34]. First-generation mTOR inhibitors refer to
rapamycin and its derivatives temsirolimus, everolimus, and
ridaforolimus [14]. Second-generation mTOR inhibitors
refer to ATP-competitive mTOR inhibitors including Torin1,
PP242, and PP30 [34]. Rapamycin represses the kinase
activity of mTOR1 by binding to the FKBP12-rapamycin
(FRB) domain of mTORC1 [35]. Since rapamycin has poor
water solubility, absorption, and low bioavailability [36],
its derivatives are developed to improve bioavailability by a
chemical modification at C-40-0 of rapamycin [37]. ATP-
competitive mTOR inhibitors suppress the catalytic activities
of both mTORC1 and mTORC2 by binding to the kinase
domain [34].
3.1. Inhibitory Effects of Rapamycin on Head and Neck Cancer.
Some studies have reported the inhibitory effects of rapa-
mycin on head and neck cancer using both in vitro cell line
model and in vivo xenograft model. Rapamycin suppressed
growth of SCC-15 cells by inhibiting phosphorylation of
mTOR in vitro [38]. Rapamycin prevented tumorigenesis
of head and neck cancer in a 4-nitroquinoline-1 oxide
carcinogenesis mice model and a k-ras and p53 two-hit
carcinogenesis mice model [39, 40]. Amornphimoltham
et al. found that rapamycin treatment significantly repressed
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Figure 1: Targeted therapies for head and neck cancer. EGFR: epidermal growth factor receptor; HER-2: human epidermal growth factor
receptor 2; VEGFR: vascular endothelial growth factor receptor; IGF-1R: insulin growth factor-1 receptor; mTOR: mammalian target of
rapamycin; NF-κB: nuclear factor-kappa B.
tumor growth of nude mice bearing xenografts derived from
human head and neck cancer cell lines HN21, CAL27, and
UMSCC11B [30]. Moreover, it was found that rapamycin
inhibited phosphorylation of S6, repressed DNA synthesis,
and induced apoptosis in xenograft model [30].
3.2. Inhibitory Effects of Temsirolimus on Head and Neck
Cancer. The therapeutic effects of temsirolimus on head and
neck cancer have also been demonstrated in several studies in
both in vitro cell line model and in vivo xenograft model.
Temsirolimus treatment inhibited cell proliferation of head
and neck cancer cell lines PCI-1 and PCI-13 in vitro
[41]. An experiment carried out by Nathan et al. also
reported that temsirolimus dose-dependently repressed the
proliferation of head and neck cell lines FaDu and FaDu9000
by inhibiting phosphorylation of 4EBP1 in vitro [42].
Furthermore, temsirolimus-treated mice showed reduced
tumor size, inhibited phosphorylation of S6, and decreased
phosphorylation of 4EBP1 in comparison to control mice
in xenograft model [42]. This study has also employed a
minimal residual disease (MRD) model to further examine
the efficacy of temsirolimus. TheMRDmodel was performed
to mimic patients with molecular positive margins. Mice
treated by temsirolimus exhibited decreased proportion of
mice with tumors, repressed tumor size, and retarded time
to develop tumors in comparison with control mice in the
MRD model [42]. Finally, it was found that temsirolimus
treatment repressed the phosphorylation of 4EBP1 in
peripheral blood mononuclear cells of mice from the MRD
model, suggesting that the phosphorylation of 4EBP1 was a
promising biomarker to monitor the response of tumors to
temsirolimus [42]. Jimeno et al. showed that temsirolimus
inhibited the growth of Detroit 562 cells to 13% in xenograft-
bearing nude mice. Furthermore, temsirolimus-treated mice
displayed a decrease in vessel intratumor growth, while
control mice showed widespread vessels in the tumors [43].
These results suggested that temsirolimus inhibited both
proliferation and angiogenesis in xenograft model.
3.3. Inhibitory Effects of Everolimus on Head and Neck Cancer.
Several studies have also reported the anticancer effects of
everolimus on head and neck cancer. Patel et al. found that
everolimus and rapamycin inhibited phosphorylated S6 in
the primary tumor site and metastatic lymph nodes of mice
with UMSCC2-derived xenografts growing in the tongue
[44]. In addition, mice treated by everolimus and rapamycin
displayed areas of squamous differentiation and fibrosis,
while control mice exhibited areas with active cell growth,
indicating that everolimus and rapamycin treatment signifi-
cantly repressed tumor growth [44]. Moreover, everolimus-
and rapamycin-treated mice showed a reduction in the num-
ber of metastatic lymph nodes, resulting in an improvement
of the overall survival of mice [44]. Molinolo et al. also
reported the inhibitory effects of everolimus and rapamycin
on xenografts derived from head and neck cancer cell line
UDSCC2 in nude mice [31].
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Figure 2: mTOR signaling pathway. PI3K: phosphatidylinositol-3-kinase; mTOR: mammalian target of rapamycin; mTORC1: mTOR com-
plex 1; mTORC2: mTOR complex 2; Raptor: regulatory-associated protein of mTOR; Rictor: rapamycin-insensitive companion of mTOR;
mSIN1: mammalian stress-activated protein kinase interacting protein; eIF4E: eukaryotic initiation factor 4E; 4EBP1: eIF4E -binding protein
1; S6K1: S6 kinase 1; PKCα: protein kinase Cα; SGK1: glucocorticoid-induced protein kinase 1.
4. Clinical Trials on mTOR Inhibitors in
Head and Neck Cancer
Although some studies have demonstrated the inhibitory
effects of mTOR inhibitors on head and neck cancer using
in vitro cell line model and in vivo xenograft model, little
evidence has been obtained from clinical trials. Because
most clinical trials were initiated from 2009 to 2011 and are
recruiting participants, it is not strange that clinical trials
have given little evidence. A phase I clinical trial showed
that temsirolimus treatment resulted in partial response in
a patient with head and neck cancer at stage T4N3M1 [45].
To evaluate the therapeutic effects of mTOR inhibitors on
patients with head and neck cancer, a large number of clin-
ical trials have been initiated (http://www.clinicaltrials.gov/)
(Table 2).
5. Therapeutic Strategies of
mTOR Inhibitors in Head and Neck Cancer
Since mTOR inhibitor alone has displayed inhibitory effects
on head and neck cancer, it has potential as a single
therapeutic agent. Furthermore, some studies have demon-
strated that combined mTOR inhibitors with radiation,
chemotherapeutic agents, or other targeted therapeutic
agents resulted in synergistic repression on head and neck
cancer.
5.1. Evidence on Temsirolimus. Combined temsirolimus with
radiotherapy displayed augmented inhibitory effects on
tumor growth than radiation alone in mice bearing xeno-
grafts derived from head and neck cancer cell lines FaDu
and SCC40. Moreover, combined temsirolimus with radio-
therapy increased survival of mice with FaDu- and SCC40-
derived xenografts. These results indicated that temsirolimus
could be used in combination with radiotherapy to treat
head and neck cancer [46]. Temsirolimus in combination
with adriamycin/cisplatin resulted in synergistic suppression
of cell proliferation of human head and neck cancer cell
line KB and its multidrug-resistant subclone KB/7D by
inhibiting the phosphorylation of 4EBP1 and S6K1 in vitro
[47]. Temsirolimus repressed tumor growth more effectively
than erlotinib (an EGFR inhibitor) in nude mice bearing
xenografts derived from Detroit 562 cells (intermediate
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Table 2: Clinical trials of mTOR inhibitors in head and neck cancer.
Drugs Treatment regimens Study phase and disease status Identifier no.
Rapamycin
Rapamycin once daily for
21 days followed by surgery
Phases I/II study in advanced
head and neck cancer
NCT01195922
Temsirolimus
Temsirolimus with or
without cetuximab
Phase II study in recurrent
and/or metastatic head and
neck cancer
NCT01256385
Temsirolimus Temsirolimus
Phase II study in
relapsed/recurrent
head and neck cancer
NCT01172769
Temsirolimus
Temsirolimus, paclitaxel,
and carboplatin
Phases I/II study in recurrent
or metastatic head and neck
cancer
NCT01016769
Temsirolimus
Temsirolimus, cisplatin,
and cetuximab
Phases I/II study in recurrent
or metastatic head and neck
cancer
NCT01015664
Everolimus
Everolimus, docetaxel, and
cisplatin
Phase I study in local-regional
advanced head and neck
cancer
NCT00935961
Everolimus
Carboplatin, cetuximab,
and everolimus
Phases I/IIB study in recurrent
metastatic head and neck
cancer
NCT01283334
Everolimus
Everolimus, carboplatin,
and paclitaxel
Phases I/II study in locally
advanced head and neck
cancer
NCT01333085
Everolimus Everolimus, cetuximab
Phase I study in recurrent or
metastatic head and neck
cancer
NCT01637194
Everolimus Everolimus
Phase II study in refractory,
recurrent, and locally
advanced head and neck
cancer
NCT01051791
Everolimus Everolimus, erlotinib
Phase II study in recurrent
head and neck cancer NCT00942734
Everolimus Everolimus, placebo
Phase II study in locally
advanced head and neck
cancer
NCT01133678
susceptibility to erlotinib), indicating that temsirolimus
has potential as a therapeutic agent for EGFR-resistant
head and neck cancer [43]. Temsirolimus augmented the
inhibitory effects of the cetuximab-bevacizumab-irradiation
combination in nude mice bearing xenografts derived from
head and neck cancer cell line CAL33 [48].
5.2. Evidence on Everolimus. Everolimus displayed inhibitory
effects on both cisplatin-resistant and cisplatin-sensitive
NPC cell lines in vitro [49]. Combination of everolimus and
cisplatin also exhibited synergistic repression on NPC cell
lines [49].
6. Conclusion
In head and neck cancer, it has been shown that mTOR sig-
naling pathway was activated, making it attractive for target-
ed therapy. Although some studies have demonstrated the
inhibitory effects of mTOR inhibitors on head and neck
cancer using in vitro cell line model and in vivo xenograft
model, little evidence has been obtained from clinical trials.
A large number of clinical trials have been initiated to evalu-
ate the clinical application of mTOR inhibitors in patients
with head and neck cancer. Combined mTOR inhibitors
with radiation, chemotherapeutic agents, or other targeted
therapeutic agents would result in synergistic repression on
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head and neck cancer, thus minimizing their toxicity and
overcoming chemoresistant tumors. In addition, mTOR and
downstream targets eIF4E, 4EBP1, S6K1, and S6 are potential
diagnostic and prognostic biomarkers for head and neck
cancer.
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